Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions

被引:9
作者
Economopoulou, Panagiota [1 ]
Pantazopoulos, Anastasios [1 ]
Spathis, Aris [2 ]
Kotsantis, Ioannis [1 ]
Kyriazoglou, Anastasios [1 ]
Kavourakis, George [1 ]
Zakopoulou, Roubini [1 ]
Chatzidakis, Ioannis [1 ]
Anastasiou, Maria [1 ]
Prevezanou, Maria [1 ]
Resteghini, Carlo [3 ]
Licitra, Lisa [3 ,4 ]
Bergamini, Cristiana [3 ]
Colombo, Elena [3 ]
Caspani, Francesca [3 ]
Denaro, Nerina [5 ]
Vecchio, Stefania [6 ]
Bonomo, Pierluigi [7 ]
Cossu Rocca, Maria [8 ]
Bertolini, Federica [9 ]
Ferrari, Daris [10 ]
Psyrri, Amanda [1 ]
Bossi, Paolo [11 ]
机构
[1] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Internal Med 2, Sect Med Oncol, Athens 12462, Greece
[2] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Pathol 2, Athens 12462, Greece
[3] Fdn IRCCS Ist Nazl Tumori, Head & Neck Med Oncol Unit, Via Venezian 1, I-20133 Milan, Italy
[4] Univ Milan, Dept Oncol & Hematooncol, I-20122 Milan, Italy
[5] Med Oncol Santa Croce & Carle Gen Hosp Cuneo, I-12100 Cuneo, Italy
[6] IRCCS Osped Policlin San Martino, I-16132 Genoa, Italy
[7] Azienda Osped Univ Careggi, Radiat Oncol, I-50134 Florence, Italy
[8] European Inst Oncol IRCCS, Dept Med Oncol Urogenital & Head & Neck Tumors Me, IEO, I-20141 Milan, Italy
[9] Univ Hosp Modena, Dept Hematol & Oncol, Med Oncol Unit, I-41125 Modena, Italy
[10] San Paolo Hosp, Med Oncol Unit, I-20142 Milan, Italy
[11] Univ Brescia, ASST Spedali Civili, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Med Oncol, I-25123 Brescia, Italy
关键词
immunotherapy; nasopharyngeal cancer; EBV DNA; nonendemic region; ANTITUMOR-ACTIVITY; PHASE-II; RECURRENT; CHEMOTHERAPY; MULTICENTER; PEMBROLIZUMAB; CAMRELIZUMAB; BIOMARKERS; CANCER; SAFETY;
D O I
10.3390/cells11010032
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited. Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8 centers in Italy. Between 2016 and 2021, 46 patients who were treated with at least one cycle of immune checkpoint inhibitors (ICI) were identified. Herein, we present our results and a review of the literature. Results: assessment of response was available in 42 patients. Overall, 11 patients responded to immunotherapy (Overall Response Rate-ORR 26.2%). Three patients had complete response (CR), and 8 patients had partial response (PR). Disease control rate (DCR) was 61.9%. Median Progression Free Survival (PFS) was 5.6 months and median Overall Survival (OS) was 19.1 months. Responders to ICI improved PFS and OS as compared to that of nonresponders. A lower probability of responding to ICI was shown in patients with more than three metastatic sites (p = 0.073), metastatic disease at initial diagnosis, (p = 0.039) or EBV DNA positive before ICI initiation, (p = 0.074). Decline in EBV DNA levels was found to be statistically significant associated with best response to ICI (p = 0.049). Safety was manageable. Conclusions: among 46 patients with R/M NPC treated with immunotherapy in two nonendemic regions, ORR was 26.2% and durable responses were observed. Low disease burden could serve as a biomarker for response to ICI.
引用
收藏
页数:10
相关论文
共 50 条
[21]   Cell-free EBV DNA as a biomarker during clinical management of nasopharyngeal carcinoma in a nonendemic region [J].
Pramanik, Raja ;
Arora, Shalabh ;
Sharma, Preity ;
Biswas, Ahitagni ;
Nayak, Baibaswata ;
Thakar, Alok ;
Sharma, Atul ;
Ghose, Sampa .
JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (02) :720-728
[22]   Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study [J].
Wu, Xiaoyue ;
Li, Yanqi ;
Zhang, Kunning ;
Guo, Zhoubo ;
Li, Yang ;
Zhao, Fangdong ;
Zhang, Tian ;
Chen, Xi ;
Wei, Hui ;
Zhang, Wencheng ;
Wang, Ping ;
Pang, Qingsong .
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2023, 38 :130-137
[23]   Integrated strategies for chemotherapy cycles in nasopharyngeal carcinoma patients: Real-world data from two epidemic centers guiding decision-making [J].
Zhan, Zejiang ;
Huang, Yingying ;
Zhou, Jiayu ;
Cai, Zhuochen ;
Huang, Haoyang ;
Deng, Ying ;
Qiu, Wenze ;
Cao, Xun ;
Chen, Xi ;
Liang, Chixiong ;
Zhang, Lulu ;
Guo, Xiang ;
Yuan, Taize ;
Lyu, Xing .
CHINESE JOURNAL OF CANCER RESEARCH, 2023, 35 (02) :126-+
[24]   The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: a real-world study [J].
Wu, Xue ;
Ding, Fangjie ;
Bao, Shunshun ;
Mu, Yiming ;
Zhang, Jiandong ;
Zhang, Shuming ;
Hu, Pingping ;
Zhang, Yan ;
Liang, Ning ;
Deng, Guodong ;
Hao, Yuying ;
Liang, Xinquan ;
Li, Fengxue ;
Shu, Yang ;
Zhang, Jingxin ;
Qiao, Lili ;
Zhang, Yingying .
FRONTIERS IN IMMUNOLOGY, 2025, 16
[25]   Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort [J].
Nguyen-Khac, Eric ;
Nahon, Pierre ;
Ganry, Olivier ;
Ben Khadhra, Hajer ;
Merle, Philippe ;
Amaddeo, Giuliana ;
Ganne-Carrie, Nathalie ;
Silvain, Christine ;
Peron, Jean-Marie ;
Mathurin, Philippe ;
Anty, Rodolphe ;
Uguen, Thomas ;
Decaens, Thomas ;
Riachi, Ghassan ;
Bouattour, Mohamed ;
Baron, Aurore ;
Bronowicki, Jean-Pierre ;
Pageaux, Georges-Philippe ;
Rosmorduc, Olivier ;
Ducournau, Gerard ;
Gilberg, Melina ;
Tanang, Alexandre ;
Dupin, Julien ;
Gilbert-Marceau, Anika ;
Blanc, Jean-Frederic .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 35 (10) :1168-1177
[26]   Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution [J].
Sotelo, Marta ;
Munoz-Unceta, Nerea ;
Matorras, Antonio ;
Jara, Pablo ;
Castro, Clara ;
Cacho, Diego ;
Caramelo, Belen ;
Azueta, Ainara ;
Duran, Ignacio .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (03) :682-688
[27]   Real-world data on the efficacy and toxicity of induction chemotherapy in locally advanced nasopharyngeal carcinoma in a non-endemic population [J].
Filho, Cassio Murilo Hidalgo ;
Polho, Gabriel Berlingieri ;
Moreira, Otavio Augusto ;
Andrade, Matheus de Oliveira ;
Parrela, Vinicius Cruz ;
Shinkado, Yumi Ricucci ;
Robatto, Amanda Acioli de Almeida ;
Neto, Felippe Lazar ;
Freitas, Ana Julia ;
Souza, Aurelio Teixeira ;
de Castro, Gilberto ;
Mak, Milena Perez .
ECANCERMEDICALSCIENCE, 2025, 19
[28]   FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study [J].
Lu, Yan-Cen ;
Yang, Yu-Chen ;
Ma, Di ;
Wang, Jun-qing ;
Hao, Feng-Jie ;
Chen, Xu-xiao ;
Chen, Yong-jun .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[29]   Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A real-world study [J].
Yu, Su-Yeon ;
Mckavanagh, Dan ;
McPherson, Ian ;
Walpole, Euan ;
Atkinson, Victoria ;
Hollingworth, Samantha .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (10) :1371-1379
[30]   Efficacy and safety of reduced-dose chemotherapy plus immunotherapy in patients with lung squamous cell carcinoma: A real-world observational study [J].
Ouyang, Ganlu ;
Liu, Yanyang ;
Liu, Jiewei ;
Huang, Lin ;
Luo, Feng ;
Li, Lu .
CANCER MEDICINE, 2023, 12 (18) :18679-18690